Longboard Pharmaceuticals, Inc. financial data

Symbol
LBPH on Nasdaq
Industry
Pharmaceutical Preparations
Location
4275 Executive Square, Suite 950, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.84K % +106%
Return On Equity -33 % +60.3%
Return On Assets -30.9 % +58.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39M shares +63.7%
Common Stock, Shares, Outstanding 34.4M shares +60.6%
Entity Public Float 148M USD +185%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 39M shares +65.9%
Weighted Average Number of Shares Outstanding, Diluted 39M shares +65.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 67.3M USD +65.1%
General and Administrative Expense 20.2M USD +65.9%
Operating Income (Loss) -87.5M USD -65.3%
Net Income (Loss) Attributable to Parent -76.3M USD -50.5%
Earnings Per Share, Basic -2.24 USD/shares +7.05%
Earnings Per Share, Diluted -2.24 USD/shares +7.05%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.6M USD +15.5%
Cash, Cash Equivalents, and Short-term Investments 288M USD +415%
Assets, Current 293M USD +402%
Other Long-term Investments 244K USD +578%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 3.73M USD +646%
Assets 297M USD +405%
Accounts Payable, Current 1.13M USD +212%
Accrued Liabilities, Current 1.89M USD +291%
Liabilities, Current 18.4M USD +173%
Operating Lease, Liability, Noncurrent 3.47M USD +3110%
Accumulated Other Comprehensive Income (Loss), Net of Tax 700K USD
Retained Earnings (Accumulated Deficit) -202M USD -60.8%
Stockholders' Equity Attributable to Parent 275M USD +429%
Liabilities and Equity 297M USD +405%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.2M USD -15.9%
Net Cash Provided by (Used in) Financing Activities 286M USD +1241%
Net Cash Provided by (Used in) Investing Activities -231M USD -3896%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 34.4M shares +60.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 40.3M USD +181%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.9M USD +16.5%
Deferred Tax Assets, Valuation Allowance 31M USD +70%
Cash and Cash Equivalents, Period Increase (Decrease) -31.3M USD -148%
Deferred Tax Assets, Gross 31.1M USD +69.1%
Operating Lease, Liability 3.73M USD +644%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -75.5M USD -50.9%
Lessee, Operating Lease, Liability, to be Paid 5.1M USD +859%
Operating Lease, Liability, Current 267K USD -32.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 785K USD +83.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 662K USD +530%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.37M USD +4460%
Lessee, Operating Lease, Liability, to be Paid, Year Three 820K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.15M USD +63%
Lessee, Operating Lease, Liability, to be Paid, Year Four 856K USD
Operating Lease, Payments 105K USD +11.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 31M USD +70%
Share-based Payment Arrangement, Expense 8.79M USD +195%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%